• Ocumetics began recruiting patients in Mexico City for Group Two surgeries of its accommodating intraocular lens, targeted for fall 2026.
• No new trial results were presented; Group Two outcomes are expected in the future once surgeries and follow-ups are completed.
• The study shifts beyond safety to assess overall safety and real-world near- and distance-vision performance.
• Group One results were previously reported as meeting or exceeding expectations; 12-month follow-ups are now being collected.
• Group Two will use a next-generation lens design paired with an upgraded delivery system, supporting the product’s clinical development path.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Ocumetics Technology Corp. published the original content used to generate this news brief via TheNewswire (Ref. ID: 202609080900TNWSWRCACNPR_____1knDFyW74) on September 08, 2026, and is solely responsible for the information contained therein.